Novartis loses global development head to Gates Foundation

pharmafile | September 14, 2011 | News story | Research and Development Bill and Melinda Gates Foundation, Novartis, appointment 

Novartis’ global head of development Trevor Mundel is to leave the company and take a senior position at The Bill and Melinda Gates Foundation.

He will remain with Novartis until 1 December, after which he will take up the role of executive director of the Foundation’s Global Health Program.

At Novartis Mundel’s responsibilities included overseeing the development of drug candidates provided by the Novartis Institutes for BioMedical Research (NIBR) or the company’s licensing partners.

Prior to joining Novartis, he worked for Warner Lambert and Pfizer in senior clinical development roles, including director in central nervous system clinical development and as head of  experimental Medicine, respectively.

Novartis said it would name Mundel’s successor shortly.

Dominic Tyer

Related Content

PeptiDream and Novartis extend peptide discovery collaboration

PeptiDream has announced the expansion of its peptide discovery collaboration with Novartis Pharma AG.

Novartis shares new data about Fabhalta for IgAN treatment

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …

chuttersnap-oijvdm3zx4i-unsplash

Novartis shares new data for Zolgensma in children with SMA

Novartis has announced new data to continue the support of the clinical benefits of Zolgensma …

Latest content